NEW YORK (GenomeWeb News) – The Genome Institute of Singapore and Sengenics said today that they have formed a partnership to identify and validate auto-antibody signatures for the early detection of cancers.
The collaboration will use protein microarray technology from Senegenics' strategic partner, Oxford Gene Technology, and will focus initially on gastric and breast cancers.
As part of the partnership, Sengenics will establish its research biomarker discovery facility at GIS this year. The goal, noted GIS Executive Director Ng Huck Hui in a statement, is to combine the antibody biomarkers discovered via the collaboration with GIS's existing proprietary genomic data to "potentially develop a new range of powerful oncology prognostic tests specific to the Singaporean population."
According to Sengenics Commercial Director Johan Poole-Johnson, the partners anticipate completing the first phase of the project within 12 months.
Financial and other terms of the agreement were not disclosed.